« Price Gouging or Not? |
| TNG1412: Was There a Warning? »
March 17, 2006
Update on TGN1412
I don't often do updates on the weekends around here, but I wanted to point out this update from the BlackTriangle blog in the UK on the TGN1412 antibody trial. Anthony Cox has all the latest information from the medical and the British press, including many details which haven't been mentioned in most reports.
For one thing, it's now being said that not only were the primate tests clean, but these first-in-man doses were set at 1/500th of the primate dose. As the latest articles in Nature and New Scientist show, there are plenty of immunologists around who are expressing doubts about TeGenaro's therapeutic approach. But it's hard to say how much of that is ex post facto - after all, a review board signed off on this, and they presumably included some competent people.
My guess is that it's going to be a long time before anyone tries another immunomodulatory antibody in humans. . .and it wouldn't surprise me to learn that it's going to be more difficult to recruit for many Phase I trials in general. That isn't good.
+ TrackBacks (0) | Category: Clinical Trials
POST A COMMENT
- RELATED ENTRIES
- Shire's Replagal Problems: An Inside Look?
- Bungled Structure, And How
- Roche Closes Nutley, Once Its US R&D Home
- The Next Five Years in the Drug Industry
- A Kinase Inhibitor Learns Something New
- The Good Ol' Friedel-Crafts
- Merck's Madagascar Marketing Mess
- Scientific Literacy: Where Do You Stop?